MultiStem OverviewWe are developing MultiStem®, our proprietary stem cell product for the treatment of diseases and conditions in the inflammatory and immune, neurological, and cardiovascular disease areas. Working with independent clinical and research institutions in the United States and Europe, we have established clinical trials in each of these areas. MultiStem is a biologic product that is manufactured from human stem cells obtained from adult bone marrow or other tissue sources. Unlike other cell types, after isolation from a qualified donor, MultiStem may be expanded on a large scale for future clinical use and stored in frozen form until needed. Cells obtained from a single donor require no genetic modification and may be used to produce banks yielding hundreds of thousands to millions of doses of MultiStem product – an amount far greater than other stem cell types can achieve. Each bank is extensively characterized to ensure product consistency and safety.
Neurological conditions and diseases impose an enormous clinical and social burden globally, and affect approximately 200 million people in the U.S., Europe and Japan. Conditions like ischemic stroke represent major causes of death and serious disability, as well as major areas of unmet medical need.
As we age, we become more susceptible to a variety of aging related diseases, such as heart disease, vascular disease and other conditions. The American heart Association has projected that the economic costs of treating heart disease are expected to be more than $818 billion annually by the year 2030.
According to the National Institutes of Health, there are more than 80 different recognized types of autoimmune disease. Collectively, these conditions affect many millions of individuals in the United States and the rest of the world and represent a substantial healthcare and socioeconomic burden.
Regenerative medicine has shown promise in many areas. Through a broad network of collaborations with leading clinical experts and researchers from around the world, we are exploring how MultiStem and related technologies may have potential to address other areas of clinical need.